Live Breaking News & Updates on உயிரியல் ப்ராடக்ட்ஸ் வழிகாட்டல்
Stay updated with breaking news from உயிரியல் ப்ராடக்ட்ஸ் வழிகாட்டல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have. ....
Share this article TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/ Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, taking place virtually. Presentations include new clinical data and in-depth analyses on the impact of Libtayo in several advanced cancers, including non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and melanoma. ....
/PRNewswire/ Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free. ....
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple . SanofiApril 19, 2021 GMT European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies Sarclisa combination therapy was associated with undetectable levels of multiple myeloma (MM) in nearly 30% of patients with relapsed MM Second EU approval in less than 12 months for Sarclisa in combination with a standard of care regimen for the treatment of relapsed or refractory MM ....